Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Rekha Pillai

Neurology Memphis, TN Medical Doctor

NPI 1356318752 CMS profile 197086

3950 New Covington Pike, Ste 270, Memphis, TN 38128

Open in the dashboard

General payments

$15,812

672 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$339,059 paid to institutions, not to them · program years 2019–2022

Through program year 2023, Rekha Pillai of Memphis, TN is reported in the CMS Open Payments database as having received $15,812 across 672 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $339,059 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,813 2
2021 General $3,609 255
2020 General $2,244 173
2019 General $8,145 242

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rekha Pillai
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rekha Pillai were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rekha Pillai Neurology median Middle half National median
2019 $8,145 $474 $118–$2,177 $163
2020 $2,244 $367 $82–$2,309 $114
2021 $3,609 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $1,813 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Genentech USA, Inc. $5,544 44 payments
  2. EMD Serono, Inc. $2,469 72 payments
  3. Teva Pharmaceuticals USA, Inc. $1,262 99 payments
  4. Novartis Pharmaceuticals Corporation $1,181 92 payments
  5. Biogen, Inc. $700 47 payments
  6. Allergan Inc. $634 52 payments
  7. Lilly USA, LLC $274 19 payments
  8. Horizon Therapeutics plc $256 9 payments
  9. SK Life Science, Inc. $240 18 payments
  10. Celgene Corporation $234 20 payments
  11. Other $3,018 200 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,718 656 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,241 13 payments
  3. Consulting Fee $1,800 1 payment
  4. Education $53 2 payments
Products named General payments · program years 2019–2023
  1. OCREVUS $5,544 44 payments
  2. AJOVY Central Nervous System $722 50 payments
  3. BOTOX $507 43 payments
  4. KESIMPTA $487 35 payments
  5. MAYZENT $472 32 payments
  6. AIMOVIG $463 38 payments
  7. Ajovy Central Nervous System $448 41 payments
  8. UPLIZNA $256 9 payments
  9. EMGALITY $249 18 payments
  10. ZEPOSIA $234 20 payments
  11. Other $4,606 339 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

2,739

Median for Neurology: 833

Drug cost

$2,500,879

Median for Neurology: $202,670

Branded share of claims

22.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliris Eculizumab Brand 12 $637,629
Ocrevus Ocrelizumab Brand 12 $483,471
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 27 $212,747
Avonex Pen (4 Pack) Interferon Beta-1a Brand 13 $183,294
Copaxone Glatiramer Acetate Brand 25 $159,834
Betaseron Interferon Beta-1b Brand 14 $140,089
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 12 $125,810
Plegridy Pen Peginterferon Beta-1a Brand 14 $111,089
Tysabri Natalizumab Brand 13 $106,736
Dimethyl Fumarate Generic 55 $88,275

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$41,407

Medicare's payments for the services billed

Medicare patients

328

Average age 73

Services billed

2,044

210 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 44%
Chronic kidney disease 33%
Ischemic heart disease 30%
Depression 30%
Alzheimer's or dementia 26%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

672 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record